Mylan And Biocon Launch Semglee Insulin Glargine In US

Seeking Biosimilar Status And Interchangeability Designation For Lantus Rival

 
• By David Wallace
  
Insulin glarine
Mylan and Biocon have introduced their Semglee insulin glargine in the US • Source: Shutterstock

More from Products

More from Generics Bulletin